Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
CGGR vs XBI: how they differ
CGGR and XBI hold 3% of their weight in the same names, and XBI returned more over the year.
Capital Group Growth ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, CGGR and XBI hold 3% of their money in the same securities at the same weight.
| Holding | CGGR | XBI |
|---|---|---|
| Vertex Pharmaceuticals Inc | 1.56% | 1.06% |
| Alnylam Pharmaceuticals Inc | 0.76% | 0.96% |
| Amgen Inc | 0.53% | 1.00% |
| Moderna Inc | 0.39% | 1.41% |
| Ionis Pharmaceuticals Inc | 0.36% | 1.00% |
| Only in CGGR | Only in XBI |
|---|---|
| Meta Platforms Inc 7.09% | Apogee Therapeutics Inc 1.49% |
| Tesla Inc 5.85% | Twist Bioscience Corp 1.41% |
| Broadcom Inc 5.40% | Oruka Therapeutics Inc 1.38% |
| NVIDIA Corp 5.16% | Kymera Therapeutics Inc 1.36% |
| Micron Technology Inc 4.86% | Viking Therapeutics Inc 1.31% |
| Microsoft Corp 4.38% | Praxis Precision Medicines Inc 1.29% |
| Alphabet Inc 3.36% | Erasca Inc 1.27% |
| Alphabet Inc 3.06% | Revolution Medicines Inc 1.21% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.
| CGGR Capital Group Growth ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Capital | State Street |
| What it is | Growth | SPDR S&P Biotech |
| Total return, 1 year | +7.2% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −10.3 pts | +46.5 pts |
| Expense ratio | 0.39% | 0.35% |
| Already in the S&P 500 | 80.6% | 8.5% |
| Holdings | 89 | 150 |
CGGR in plain words
CGGR is an index equity fund tracking the Growth. Over the year to Sep 11, 2026 it returned +7.2% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.39% a year. By its holdings filed for May 31, 2026, 81% of the fund by weight is stocks the S&P 500 also holds, across 89 positions, with the top ten at 44.2%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, CGGR or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, CGGR returned +7.2% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, CGGR or XBI?
- CGGR charges 0.39% a year and XBI charges 0.35%, so XBI is cheaper. Fees come from each fund's prospectus.
- How much do CGGR and XBI overlap with the S&P 500?
- By their latest filed holdings, 81% of CGGR and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 3% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, CGGR against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/CGGR-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources